Meet Deuteria Pharmaceuticals, winner of the 2012 Buzz of BIO competition.
What is Buzz of BIO?
Companies from around the world enter for the chance to win free registration and a company presentation in the BIO Business Forum.
Deuteria Pharmaceuticals, Inc., a company that is pioneering ‘Deuterium-Enabled Chiral Switching’ (DECS) to improve the profile of drugs that interconvert between enantiomers both in vitro and in vivo. Stabilizing the preferred isomer improves the product profile. Representative drugs include Revlimid®, Actos®, Aricept®, Wellbutrin® and Effient®. Introducing deuterium enables dosing of a single, deuterated enantiomer to create an improved NCE with new composition of matter patent protection. Founded in 2010, Deuteria is a virtual biotechnology company based in the Boston area.
What did they say?
“As an emerging company with a pioneering approach to therapeutics, Deuteria Pharmaceuticals is pleased to be recognized by the premier conference in the biotechnology industry,” said Sheila DeWitt, President. “This recognition
from BIO 2012 provides and strengthens the visibility of Deuteria Pharmaceuticals.”
What did BIO say?
“The Buzz of BIO competition is an exciting opportunity for emerging companies to capture the spotlight and level the playing field a bit amongst their more established industry peers,” said Jim Greenwood, President and CEO of the Biotechnology Industry Organization. “As a Buzz winner, this company will now enter the Convention with a heightened sense of anticipation and buzz, allowing for endless partnering opportunities.”
What is the prize?
As the winner, Deuteria Pharmaceuticals received complimentary registration to the Convention with partnering, and a 15-minute Company Presentation in the BIO Business Forum®.